KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angi...

Full description

Bibliographic Details
Main Authors: Áron Kristof Ghimessy, Áron Gellert, Erzsebet Schlegl, Balazs Hegedus, Erzsebet Raso, Tamas Barbai, Jozsef Timar, Gyula Ostoros, Zsolt Megyesfalvi, Balazs Gieszer, Judit Moldvay, Ferenc Renyi-Vamos, Zoltan Lohinai, Mir Alireza Hoda, Thomas Klikovits, Walter Klepetko, Viktoria Laszlo, Balazs Dome
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
bevacizumab
non-small-cell lung cancer
advanced-stage lung adenocarcinoma
platinum-based chemotherapy
kras mutation
Online Access:https://www.mdpi.com/2072-6694/11/10/1514

Internet

https://www.mdpi.com/2072-6694/11/10/1514

Similar Items